AVIR Atea Pharmaceuticals, Inc.

NASDAQ
$3.99

Atea Pharmaceuticals, Inc. (AVIR) is expected to report earnings on February 8, 2027, after the market close. The consensus earnings estimate is a loss of $0.44 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -9.3% since its last earnings release on November 9, 2026.

Atea Pharmaceuticals Beat Consensus Estimates
Monday, November 9, 2026 · 4:05 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 8
Monday · 4:05 PM ET
Earnings Whisper
-
vs ($0.44)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $4.13

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering, developing, and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.